Synthesis and therapeutic effect of styrene–maleic acid copolymer‐conjugated pirarubicin

Cancer Science - Tập 106 Số 3 - Trang 270-278 - 2015
Kenji Tsukigawa1,2, Long Liao2, Hideaki Nakamura1,2, Jun Fang1,2, Khaled Greish2, Masaki Otagiri1,2, Hiroshi Maeda2
1Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
2Institute for Drug Delivery Science, Sojo University, Kumamoto, Japan

Tóm tắt

Previously, we prepared a pirarubicin (THP)‐encapsulated micellar drug using styrene–maleic acid copolymer (SMA) as the drug carrier, in which active THP was non‐covalently encapsulated. We have now developed covalently conjugated SMA‐THP (SMA‐THP conjugate) for further investigation toward clinical development, because covalently linked polymer–drug conjugates are known to be more stable in circulation than drug‐encapsulated micelles. The SMA‐THP conjugate also formed micelles and showed albumin binding capacity in aqueous solution, which suggested that this conjugate behaved as a macromolecule during blood circulation. Consequently, SMA‐THP conjugate showed significantly prolonged circulation time compared to free THP and high tumor‐targeting efficiency by the enhanced permeability and retention (EPR) effect. As a result, remarkable antitumor effect was achieved against two types of tumors in mice without apparent adverse effects. Significantly, metastatic lung tumor also showed the EPR effect, and this conjugate reduced metastatic tumor in the lung almost completely at 30 mg/kg once i.v. (less than one‐fifth of the maximum tolerable dose). Although SMA‐THP conjugate per se has little cytotoxicity in vitro (1/100 of free drug THP), tumor‐targeted accumulation by the EPR effect ensures sufficient drug concentrations in tumor to produce an antitumor effect, whereas toxicity to normal tissues is much less. These findings suggest the potential of SMA‐THP conjugate as a highly favorable candidate for anticancer nanomedicine with good stability and tumor‐targeting properties in vivo.

Từ khóa


Tài liệu tham khảo

10.7164/antibiotics.32.1082

10.7164/antibiotics.36.312

10.1203/00006450-200202000-00021

10.7164/antibiotics.37.1697

Matsumura Y, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387

10.1016/j.addr.2010.04.009

10.1016/j.jconrel.2004.03.027

10.1016/j.biomaterials.2006.11.051

10.1021/bc040297g

10.1007/BF02980037

10.1016/j.ijpharm.2007.05.066

10.1016/j.jconrel.2011.03.027

10.1021/mp2005966

10.1016/j.jconrel.2013.06.039

10.1038/bjc.1997.116

10.1002/(SICI)1097-0215(19971114)73:4<607::AID-IJC24>3.0.CO;2-4

10.1177/088391158800300401

10.1016/j.jconrel.2011.09.098

10.1258/ebm.2009.009304

10.1016/j.jconrel.2007.08.016

10.1021/bc040241m

10.1016/j.jconrel.2013.11.011

10.1016/S1040-8428(97)00015-2

10.1016/j.jconrel.2008.05.010

10.1016/j.jconrel.2011.04.025

Maeda H, 1979, Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent‐ and water‐soluble polymer‐conjugated protein, Gan, 70, 601

Takeshita J, 1982, In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid‐styrene)‐conjugated neocarzinostatin, SMANCS, Gan, 73, 278

10.1002/1097-0142(19870501)59:9<1560::AID-CNCR2820590905>3.0.CO;2-J

10.1159/000165380

10.1111/j.1349-7006.2010.01619.x

10.1111/cas.12152

10.3181/00379727-181-42218

Suzuki F, 1990, Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer‐conjugated derivative of neocarzinostatin, Cancer Res, 50, 3897

Suzuki F, 1988, Interferon induction by SMANCS: a polymer‐conjugated derivative of neocarzinostatin, Anticancer Res, 8, 97

Masuda E, 1996, Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer, Cancer Res, 56, 1868

Thông tin
Thông tin xuất bản

Cancer Science

Tập 106 Số 3

270-278

Thông tin tác giả